Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of “Buy” by Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received an average recommendation of “Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $64.86.

ARCT has been the topic of a number of recent analyst reports. William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday. Finally, Canaccord Genuity Group cut their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, May 10th.

Arcturus Therapeutics Stock Down 9.2 %

Shares of NASDAQ ARCT opened at $21.48 on Wednesday. The company’s fifty day moving average is $29.99 and its 200-day moving average is $32.57. The stock has a market cap of $578.46 million, a price-to-earnings ratio of -5.49 and a beta of 2.65. Arcturus Therapeutics has a twelve month low of $17.52 and a twelve month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.17. The company had revenue of $38.01 million for the quarter, compared to analysts’ expectations of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. On average, research analysts anticipate that Arcturus Therapeutics will post -4.39 EPS for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total value of $1,040,260.00. Following the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at approximately $17,902,394.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock worth $64,564,000 after purchasing an additional 146,141 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Arcturus Therapeutics by 11.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock worth $34,336,000 after purchasing an additional 115,087 shares during the last quarter. FMR LLC increased its stake in shares of Arcturus Therapeutics by 8.6% during the 3rd quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock worth $24,024,000 after purchasing an additional 74,081 shares during the last quarter. Granahan Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 12.9% during the 4th quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock worth $14,200,000 after purchasing an additional 51,504 shares during the last quarter. Finally, Great Lakes Advisors LLC acquired a new position in shares of Arcturus Therapeutics during the 4th quarter worth about $6,531,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.